The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- (ISIN Code: ES0167733015, ORY), a clinical-stage ...

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...

After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.

The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell ...

Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) ...

The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...

LeukemiaANT308 has shown strong single-agent anti-leukemia activity in 2 mouse models.   (2) Pancreatic cancerANT308 has shown synergistic effects with anti-PD-1 checkpoint inhibitors in 3 pancreatic ...

The FDA has approved Grafapex (treosulfan) for use in combination with fludarabine as a preparative regimen for allogeneic HSCT in patients aged 1 year and older with AML or MDS.

TBI remained significantly associated with reduced adjusted risks of grade 3 to 4 aGVHD and moderate-severe cGVHD.